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Experimental nonhuman primatemodels of asthma ex-
hibit multiple features that are characteristic of an eosi-
nophilic/T helper 2 (Th2)-high asthma subtype, charac-
terized by the increased expression of Th2 cytokines
and responsive genes, in humans. Here, we determine
themolecular pathways that are present in a house dust
mite–induced rhesus asthma model by analyzing the
genomewide lung gene expression profile of the rhesus
model and comparing it with that of human Th2-high
asthma. We find that a prespecified human Th2 inflam-
mation gene set from human Th2-high asthma is also
present in rhesus asthma and that the expression of the
genes comprising this gene set is positively correlated
in human and rhesus asthma. In addition, as in human
Th2-high asthma, the Th2 gene set correlates with phys-
iologic markers of allergic inflammation and disease in
rhesus asthma. Comparison of lung gene expression
profiles from human Th2-high asthma, the rhesus
asthma model, and a common mouse asthma model
indicates that genes associated with Th2 inflammation
are shared by all three species. However, some patho-
physiologic aspects of human asthma (ie, subepithelialfibrosis, angiogenesis, neural biology, and immune host
defense biology) are better represented in the gene ex-
pression profile of the rhesus model than in the mouse
model. Further study of the rhesus asthma model may
yield novel insights into the pathogenesis of human
Th2-high asthma. (Am J Pathol 2011, 179:1667–1680; DOI:
10.1016/j.ajpath.2011.06.009)
Asthma is characterized by variable airflow obstruction, air-
way hyperreactivity, and chronic airway inflammation. De-
spite these common clinical features, asthma is a hetero-
geneous disease that can be subclassified by a number of
different measures, including the nature of the airway in-
flammation.1,2 Airway eosinophilia, a hallmark of T helper 2
(Th2) inflammation, defines a major subtype of severe
asthma, with other major subtypes defined by neutrophilic
and paucigranulocytic inflammation.1–4 Recent analyses of
airway gene expression in mild-to-moderate asthmatics not
being treated with corticosteroids defines a molecular sig-
nature of Th2 inflammation that correlates with airway and
peripheral eosinophilia, airway hyperreactivity, subepithelial
fibrosis, distinct patterns of mucin expression, and elevated
IgE.5,6 The Th2-high subtype of asthma in mild-to-moderate
asthmatics is associated with the cytokines IL-5 and IL-13
and is correlated with a clinical response to inhaled corti-
costeroid treatment.
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to study pathogenic mechanisms and the efficacy of ther-
apies, given the close similarities between monkeys and
humans.7–13 Several features of lung and immune biology
in nonhuman primates more accurately model human
biology than the mouse, which is the most commonly
used animal species for preclinical asthma studies.8 For
example, in both humans and rhesus monkeys the pri-
mary distal airway is the respiratory bronchiole, whereas
in rodents it is the nonalveolarized bronchiole. Basal cells
are found throughout the tracheobronchial airways of
both humans and rhesus monkeys but only in the tra-
cheas of mice. In addition, Clara cells are found only in
the bronchioles of both humans and rhesus monkeys but
throughout the tracheobronchial airways of mice. Some
unique features of asthma found in humans and rhesus
monkeys but not mice include intrinsic airway hyperreac-
tivity (except for the A/J mouse strain), smooth muscle
hypertrophy in the more distal bronchi and respiratory
bronchioles, exfoliation of epithelial sheets, and mast cell
infiltration of airway smooth muscle.11,14,15 Thus, the
study of nonhuman primate models of asthma is an im-
portant complement and supplement to studies of mouse
asthma models in preclinical asthma research.
Gene expression profiling of disease tissues enables
the genomewide assessment of molecular pathways that
are dysregulated in disease. Although several groups
have performed genomewide transcriptional profiling of
preclinical mouse asthma models,16–24 and a few publi-
cations have assessed gene expression in nonhuman
primate asthma models,10,25,26 data are limited on
genomewide gene expression in nonhuman primate
asthma models, and we are not aware of any publications
that have directly compared the genomewide transcrip-
tional profiles of human asthma with those of any preclin-
ical asthma model, regardless of species.
A model of allergic asthma induced in rhesus monkeys
by house dust mites (HDMs) exhibits multiple pathophys-
iologic features of human allergic asthma and has been
used to assess the efficacy of immunomodulatory thera-
pies.9–12 Here, we have conducted gene expression pro-
filing of lung airway samples from this rhesus asthma
model. We assess the relation between rhesus lung gene
expression and physiologic parameters of inflammation
and disease. In addition, we compare lung gene expres-
sion of human Th2-high asthma with that of the rhesus
asthma model, as well as that of a commonly used mouse
asthma model, to assess similarities and differences in
lung gene expression between human Th2-high asthma
and these two animal models of asthma.
Materials and Methods
Human Subjects
Bronchial biopsy RNA from 27 nonsmoking patients with
mild-to-moderate asthma and healthy nonsmoking sub-
jects were obtained from the University of California San
Francisco Airway Tissue Bank, a specimen biorepository
approved by the University of California San FranciscoCommittee on Human Research. Endobronchial biopsies
had been collected from a subset of patients for whom
we have previously described gene expression profiles
of bronchial epithelial brushings.6,27 Three to six endo-
bronchial biopsies were collected from the carinae of the
second- to fourth-order bronchi. Informed consent was
obtained from all human subjects.
Rhesus Model of Allergic Asthma
An HDM-induced allergic asthma model in young adult
rhesus monkeys (Macaca mulatta) has been described
previously.12 The model consisted of an 18-month dis-
ease development phase, followed by a treatment phase.
Data from the treatment phase was published previ-
ously.12 Data from the 18-month disease development
phase is presented in this article. The animal protocol
was approved by the Institutional Animal Care and Use
Committee Ethical Review Board at the University of Cal-
ifornia Davis. All monkeys were selected from the Califor-
nia National Primate Research Center’s breeding colony
on the basis of social rank, treated with ivermectin sub-
cutaneously at 0.2 mg/kg for potential parasites, and
isolated indoors for 1 month. Briefly, 12 adult rhesus
monkeys were sensitized with a subcutaneous injection
of HDM allergen extract followed by 3 biweekly intranasal
instillations of HDM and 6 weekly aerosol challenges of
HDM. Ten adult rhesus monkeys were subjected to con-
trol treatment with PBS injections and mock aerosol chal-
lenges. After the sensitization procedure, sensitized mon-
keys were regularly exposed to aerosolized HDM for 2 to
3 hours twice a week, for a total of 18 months, and also
received additional subcutaneous and intranasal HDM
boosts at weeks 56, 71, and 75. Although all 12 sensi-
tized animals were enrolled and characterized for the
duration of the study, only 4 of the 10 control animals
were kept and characterized beyond the postsensitiza-
tion time point, because of cost constraints. The six con-
trol animals that were dropped from the study were ran-
domly selected for exclusion such that there were no
differences in the mean group values of measured pa-
rameters in the control group between the 4-animal sub-
set and the entire group of 10 control animals. Data and
samples were collected over a 2-week period, starting at
weeks 4 to 8 for the presensitization time point, week
15 for the postsensitization time point, and week 75 for
the 18-month time point, whereby week 0 denotes the
beginning of the sensitization protocol. In the first week of
data and sample collection, peripheral blood and serum
samples were obtained just before an aerosol challenge
for determination of complete blood counts, flow cytomet-
ric analysis, and serum ELISAs. Blood leukocyte values
and differential counts were determined as described
previously.11 Forty-eight hours after the aerosol chal-
lenge, pulmonary mechanics and airway hyperreactivity
to methacholine were determined as described previ-
ously.11 In the second week of data and sample collec-
tion, bronchoalveolar lavage fluid (BALF) samples were
collected 48 hours after an aerosol challenge for deter-
mination of leukocyte differentials and flow cytometric
analysis, as described previously.11 Immediately after
Lung Gene Expression in Rhesus Asthma 1669
AJP October 2011, Vol. 179, No. 4the BALF collection, five lung biopsies were obtained
from the subcarina at the lower or middle lobes of the
lung by flexible bronchoscopy with the use of a 1-mm
biopsy forceps, after intubation with an appropriate-
sized, cuffed endotracheal tube. Animals were deprived
of food 8 hours before the bronchoscopy to minimize the
risk of aspiration during anesthesia. During the bronchos-
copy procedure, oxygen saturation and heart rate moni-
toring were provided continuously, and supplemental
oxygen was routinely given. The bronchoscope (2.7 to
3.6 mm in diameter; Olympus, Center Valley, PA) was
passed through the nose, 5 mg of lidocaine was instilled
on the larynx for topical anesthesia, and the broncho-
scope was directed into the trachea. A second dose of 5
mg of lidocaine was administered through the broncho-
scope for topical anesthesia and to reduce the cough
reflex, and the bronchoscope was directed to the thin
shelf of tissues dividing segmental or subsegmental air-
ways. Three biopsies were preserved in RNAlater RNA
stabilization reagent (Qiagen, Valencia, CA) for RNA ex-
traction and gene expression profiling, and two biopsies
were reserved for histopathology analyses. Intradermal
skin testing for reactivity to HDM antigen was performed
as described previously11 at approximately 5 months
before the start of sensitization for the presensitization
time point and at week 5 for the postsensitization time
point, whereby week 0 denotes the beginning of the
sensitization protocol. During all data and sample collec-
tion, animals were sedated with ketamine (10 mg/kg, i.m.)
and then anesthetized with propofol (0.1 to 0.2 mg/kg/
min, i.v.), with the dose adjusted as deemed necessary
by the attending veterinarian.
Flow Cytometry
Peripheral blood mononuclear cells and BALF cells were
prepared for immunofluoresence staining and analyzed
by flow cytometry on a FACSCalibur flow cytometer (BD
Biosciences, Franklin Lakes, NJ).
Total and HDM-Specific IgE ELISAs
Total IgE in rhesus monkey sera was measured by ELISA
with the use of monoclonal anti-IgE MAE11 (Genentech,
South San Francisco, CA) for capture and peroxidase-
conjugated goat anti-human IgE antibody (Kirkegaard
and Perry Laboratories, Gaithersburg, MD) for detection.
The standard range was 0.098 to 12.5 ng/mL for human
IgE. The minimum sample dilution was 1:10 to avoid any
interference from sera in the assay. Rhesus monkey IgE
concentrations were calculated by dividing the concen-
trations obtained on the basis of a human IgE standard
curve by a correlation factor of 0.029, which was deter-
mined with purified cynomolgus monkey IgE (Genen-
tech). HDM-specific IgE titers were measured by ELISA
with the use of monoclonal anti-IgE MAE11 for capture
and biotinylated HDM allergen Der f1 (Indoor Biotechnol-
ogies, Charlottesville, VA) for detection, followed by
horseradish peroxidase–conjugated streptavidin (GE
Healthcare, Little Chalfont, Buckinghamshire, UK). For
calculation of titers, a cut point was set at twice theabsorbance of a 1:100 diluted blank rhesus monkey se-
rum (Bioreclamation, Westbury, NY). The dilution factor at
which an absorbance value equaled the cut point was
calculated from a linear interpolation of absorbance val-
ues obtained from serial dilutions of samples. Titer is
reported as the log10 of the dilution factor. Titers for
negative samples are reported as 1.52 because a min-
imum sample dilution factor of 33.3 was used.
Histopathology
Biopsies were placed individually in cryomolds and sub-
merged in optimal cutting temperature compound media
(Sakura Finetek, Torrance, CA). Cryomolds were then
chilled to set optimal cutting temperature compound and
stored at 80°C. All sections were cut 5-m thick and
stained with H&E for histologic analysis. All biopsies were
scored in a blinded manner at the time of collection.
Microarray Gene Expression Profiling
Human lung airway biopsy RNA was isolated from ho-
mogenized bronchial biopsies as described previ-
ously.5,6 Total RNA was extracted from individual biopsy
samples with the use of RNeasy Mini Kits (Qiagen), fol-
lowing the manufacturer’s guidelines, and all biopsy RNA
from each individual subject was pooled for further pro-
cessing and analysis. RNA samples were quantified with
a Nanodrop ND-1000 UV-spectrophotometer (Thermo
Scientific, West Palm Beach, FL), and RNA quality was
assessed with an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Palo Alto, CA). The quantity of total RNA used in
a two-round amplification protocol ranged from 10 ng to
50 ng per sample. First-round amplification and second-
round cDNA syntheses were done with the Message
Amp II aRNA Amplification Kit (Applied Biosystems, Fos-
ter City, CA). Cyanine-5 dye was incorporated with the
Quick Amp Labeling kit (Agilent Technologies). Each
cyanine-5–labeled test sample (750 ng) was pooled with
cyanine-3–labeled Universal Human Reference RNA
(Stratagene, La Jolla, CA) and hybridized onto Agilent
Whole Human Genome 4  44K arrays as described in
the manufacturer’s protocol. Arrays were washed, dried,
and scanned on the Agilent scanner according to the
manufacturer’s protocol. Microarray image files were an-
alyzed with Feature Extraction software 9.5 (Agilent Tech-
nologies). Human lung airway biopsy microarray data
have been deposited in Gene Expression Omnibus with
the accession code GSE23611.
Rhesus lung airway biopsies were recovered from
RNAlater and homogenized in RLT buffer (Qiagen) with
the use of an MM300 mixer mill (Retsch, Haan, Germany).
RNA was isolated from homogenized tissue with the use
of RNeasy Micro Kits (Qiagen) with on-column DNase
treatment, following the manufacturer’s guidelines, and
concentrated by ethanol precipitation. RNA samples
were quantified with a Nanodrop ND-1000 UV-spectro-
photometer (Thermo Scientific), and RNA quality was as-
sessed with an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies). Subsequently, RNA was amplified with the Low
RNA Input Fluorescent Linear Amplification protocol (Agi-
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linear amplification was performed to incorporate Cya-
nine-3 and Cyanine-5 label into cRNA. Each Universal
Human Reference (Stratagene) cRNA labeled with Cya-
nine-3 and test sample cRNA labeled with Cyanine-5
(750 ng) was fragmented for 30 minutes at 60°C before
loading onto Agilent Whole Human Genome microarrays
(Agilent Technologies). Samples were hybridized for 18
hours at 60°C with constant rotation. Microarrays were
washed, dried, and scanned on the Agilent scanner ac-
cording to the manufacturer’s protocol. Microarray image
files were analyzed with Feature Extraction software ver-
sion 7.5 with default parameters and Lowess normaliza-
tion to yield summary ratio data (Agilent Technologies).
Rhesus lung airway biopsy microarray data have been
deposited in Gene Expression Omnibus with the acces-
sion code GSE23327.
Statistical and Bioinformatic Analyses
Rhesus model data were expressed as mean  SD.
P values were calculated with JMP version 8.0.1 (SAS
Institute, Cary, NC). A Wilcoxon/Kruskal–Wallis Test (rank
sums) was used to compare the sensitized and nonsen-
sitized groups. P values  0.05 were considered signif-
icant.
Figure 1. Sensitization to HDM antigen induces allergic inflammation and air
a subcutaneous injection of HDM antigen extract and intranasal HDM, follow
of 18 months. Sensitized rhesus monkeys also received additional subcutane
subjected to control treatment with PBS injections and mock aerosol challen
15 for the postsensitization time point, and week 75 for the 18-month time p
sensitized and all 10 nonsensitized monkeys, except for the 18-month tim
nonsensitized monkeys. BALF eosinophils (A), serum HDM IgE titers (B), pe
airway hyperreactivity to methacholine (F) in sensitized and nonsensitize
hyperreactivity is expressed as EC150, the effective concentration of methach
lower EC150 indicates greater airway hyperreactivity. Data are expressed as mean 
(rank sums).For analysis of human gene expression microarray
data, all statistical calculations were performed with R for
Windows version 2.9.2, JMP version 8.0.1 (SAS Institute),
and Partek Genomics Suite 6.5 (Partek Incorporated, St
Louis, MO). Probes with features 50% present were
removed before each statistical test. Differential gene
expression analysis between [Th2-high asthma] and
[Th2-low asthma AND healthy control] was conducted by
Welch’s t-test, because of unequal sample sizes (14 and
26, respectively), and unequal variances were detected
by Bartlett’s test among array features.
For analysis of rhesus gene expression microarray
data, all statistical calculations were performed with the R
Project software package, version 2.10.0. Linear model-
ing was performed with the Limma package of Biocon-
ductor. Control probes, probes exhibiting CVs in the low-
est quartile, and probes without Entrez Gene annotation
were excluded. In cases in which multiple probes
mapped to the same Entrez Gene record, the probe with
the highest CV was retained, and the others were ex-
cluded. Moderated t-statistics from modeling were used
to calculate adjusted P values with the use of the method
of Benjamini–Hochberg. Probes were defined as differ-
entially expressed when the false discovery rate was
20%. Correlation coefficients between gene expression
and physiologic parameters were performed with Spear-
erreactivity in rhesus monkeys. Twelve rhesus monkeys were sensitized with
gular exposure to aerosolized HDM for 2 to 3 hours twice a week, for a total
intranasal HDM boosts at weeks 56, 71, and 75. Ten rhesus monkeys were
a were collected at week 4 to 8 for the presensitization time point, week
ereby week 0 denotes the beginning of the sensitization protocol, for all 12
, whereby data were collected for all 12 sensitized and only 4 of the 10
blood (PB) eosinophils (C), BALF lymphocytes (D), total serum IgE (E), and
s at presensitization, postsensitization, and 18-month time points. Airway








oline reSD. *P  0.05 versus nonsensitized animals, Wilcoxon/Kruskal-Wallis Test
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lated with algorithm AS 89 and adjusted with Storey’s
q-value method. For comparison of human, rhesus, and
mouse gene expression microarray data, expression
data from murine studies were linked to orthologous hu-
man genes with the use of National Center for Biotech-
nology Information annotation: first, GenBank transcript
annotation for each human or murine probe was linked to
a gene of the same species by GenBank annotation;
second, human and mouse genes were linked by
Homologene cluster data. Statistical thresholds for deter-
mining differential expression in the animal models were
Figure 2. Sensitization to HDM antigen induces airway inflammation in
rhesus monkeys. A: Inflammatory cell infiltration of the airway lamina pro-
pria was assessed in lung biopsies from sensitized and nonsensitized mon-
keys at presensitization, postsensitization, and 18-month time points. Origi-
nal magnification, 40; H&E. Green arrows indicate lamina propria. No
difference is seen in lamina propria cellularity between groups in the pre-
sensitization biopsies. Increased lamina propria cellularity is seen in sensi-
tized animals at the postsensitization and 18-month time points. B: An
increase in inflammation is observed in the sensitized versus nonsensitized
group biopsies at the postsensitization and 18-month time points. Inflamma-
tion was scored in the lamina propria underlying airway epithelium, when
assessable; 0 indicates no inflammatory infiltrate; 1, minimal inflammation/
rare scattered immune cells; 2, mild inflammation/scattered immune cells; 3,
moderate inflammation/immune cell clusters; and 4, severe inflammation/
diffuse immune cell infiltrate. Individual animal scores are shown as individ-
ual circles, with the mean inflammation score for a group of animals indi-
cated as a line. *P  0.0001 (mean inflammation score) versus nonsensitized
animals, Dunnett’s test.P value was 0.05 and fold change was 1.2.Results
A Rhesus Asthma Model Exhibits Features of
Allergic/Th2 Inflammation
We developed a model of allergic asthma in rhesus mon-
keys, as described previously,12 in which 12 adult rhesus
monkeys were sensitized to HDM allergen and 10 adult
rhesus monkeys were subjected to mock sensitization.
During 18 months of disease development and progres-
sion, we assessed lung physiologic parameters (pulmo-
nary mechanics and airway hyperreactivity to met-
hacholine), lung inflammatory parameters (BALF cell
composition and histology of lung airway biopsies), and
systemic parameters (total and HDM-specific serum IgE,
complete peripheral blood count, and skin test reactivity
to HDM) at presensitization, 15-week postsensitization,
and 18-month time points. Overall, animals in the sensi-
tized group developed several physiologic features of
asthma, including airway hyperreactivity, lung inflamma-
tion, and systemic allergic sensitization, with some heter-
ogeneity in disease parameters on an animal-to-animal
basis, as would be expected in an outbred population of
rhesus monkeys. These physiologic features of disease
are comparable to those observed in previous studies of
the rhesus asthma model9–11 and are also similar in mag-
nitude to those observed in human asthma.
Figure 3. A Th2 inflammation gene set is shared and correlated in lung airway
biopsies of human asthma and a rhesus asthma model. A: Each gene in a
previously defined human asthma epithelial three-gene set is increased in rhesus
asthma biopsies. Microarray signal ratios for periostin (Agilent probe ID
A_24_P347411), CLCA1 (Agilent probe ID A23_P153185), and serpinB2 (Agilent
probe ID A_23_P51217) are expressed as mean  SD. *P  0.05 versus non-
sensitized animals, t-test. B: A previously defined human asthma biopsy 79-gene
set is correlated in human and rhesus asthma (Pearson’s correlation coefficient
  0.495; P  4.5  107). The fold change for each of 93 Agilent probes
corresponding to 79 uniquely annotated genes is compared for human Th2-high
asthma (versus Th2-low asthma and healthy controls) and rhesus asthma (versus
nonsensitized animals). Each point corresponds to one probe, but for clarity only
a subset of the 93 probes is labeled.
conce
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HDM-specific serum IgE titers increased in sensitized ani-
mals during the disease development phase at both the
postsensitization and 18-month time points. Sensitized an-
imals also exhibited a statistically significant increase in
BALF neutrophils and in the extent of activated CD4 T cells
in the BALF (see Supplemental Figure S1 at http://ajp.
amjpathol.org). Peripheral blood eosinophils (Figure 1C),
total BALF lymphocytes (Figure 1D), and total serum IgE
(Figure 1E) were not significantly different between the sen-
sitized and nonsensitized animals and did not change dur-
ing the disease development period. Blinded scoring of
histologic analysis of airway biopsies was consistent with
the development of airway inflammation in the sensitized
group. Although the small size of the rhesus monkeys cre-
ated challenges for biopsy collection and quality, mild-to-
moderate airway inflammation was apparent in most of the
sensitized animals from which data could be obtained (Fig-
ure 2, A and B; see also Supplemental Table S1 at http://
ajp.amjpathol.org). In addition, all sensitized animals devel-
oped skin test reactivity to HDM that was apparent at both
the postsensitization and the 18-month time points (see






10344 CCL26 Chemokine (C-C motif) ligand 26
84171 LOXL4 Lysyl oxidase-like 4
4843 NOS2A Nitric oxide synthase 2A (inducible, he
948 CD36 CD36 molecule (thrombospondin rece
1012 CDH13 Cadherin 13, H-cadherin (heart)
58494 JAM2 Junctional adhesion molecule 2
51751 HIGD1B HIG1 domain family, member 1B
1179 CLCA1 Chloride channel, calcium activated, f
7855 FZD5 Frizzled homolog 5 (Drosophila)
1470 CST2 Cystatin SA
3497 IGHE Immunoglobulin heavy chain epsilon
522 ATP5J ATP synthase, H transporting, subun
246 ALOX15 Arachidonate 15-lipoxygenase
26998 FETUB Fetuin B
13 AADAC Arylacetamide deacetylase (esterase)
84969 C20orf100 TOX high mobility group box family m
116372 LYPD1 LY6/PLAUR domain containing 1
116159 CYYR1 Cysteine/tyrosine-rich 1
9951 HS3ST4 Heparan sulfate (glucosamine) 3-O-su
1469 CST1 Cystatin SN
3881 KRT31 Keratin 31
7850 IL1R2 Interleukin 1 receptor, type II
390010 NKX1-2 NK1 homeobox 2
79861 TUBAL3 Tubulin, alpha-like 3
5587 PRKD1 Protein kinase D1
*Mean fold increase in expression of a gene in the Th2-high subset o
asthma subset and the healthy control subjects).
†Mean fold-increase in expression of a gene in sensitized rhesus mo
‡Correlation coefficient.
§Nominal P value from the Spearman’s correlation test.
¶Airway hyperreactivity is expressed as EC150, whereby a lower EC1
indicate a positive correlation with airway hyperreactivity.
Data have passed threshold for significance (P  0.069) at a false d
PB, peripheral blood; AHR, airway hyperreactivity; EC150, the effective
of baseline.Supplemental Table S2 at http://ajp.amjpathol.org).The sensitized group was selected to have a greater
average intrinsic airway hyperreactivity to methacholine
than the nonsensitized group at the presensitization time
point, to model the intrinsic airway hyperreactivity observed
in human asthma. With the use of a definition of airway
hyperreactivity of amethacholine EC150 value of8mg/mL,
which is similar to the definition of airway hyperreactivity in
human asthmatics,28 4 of the 12 animals in the sensitized
group and none of the animals in the nonsensitized group
were hyperreactive before sensitization. Both sensitized and
nonsensitized groups had increased airway hyperreactivity at
the postsensitization time point, compared with the presensiti-
zation time point (Figure 1F). However, many more animals in
the sensitized group were hyperreactive at the postsensitiza-
tion time point, compared with the nonsensitized group (9 of
the 12 animals in the sensitized group were hyperreactive,
whereas only 1 of the 10 animals in the nonsensitized group
was hyperreactive). When we compared all 12 animals in the
sensitized groupwith all 10 animals in the nonsensitized group
at the presensitization and postsensitization time points, we
found no statistically significant difference in the change in
airway hyperreactivity between the groups, because of mini-










4.06 3.22 0.736 0.001
1.27 1.53 0.653 0.005
tes) 1.39 1.42 0.245 0.328
1.66 1.33 0.211 0.401
1.24 1.30 0.433 0.073
1.40 1.29 0.513 0.029
1.54 1.18 0.159 0.528
ember 1 5.76 1.17 0.311 0.209
1.42 1.16 0.384 0.116
2.78 1.13 0.449 0.062
2.57 1.12 0.441 0.067
1.42 1.12 0.382 0.118
1.44 1.12 0.132 0.602
3.34 1.12 0.602 0.008
1.48 1.10 0.138 0.585
2 1.44 1.08 0.518 0.028
1.44 1.08 0.583 0.011
1.24 1.07 0.306 0.444
ferase 4 2.78 1.06 0.5 0.035
3.21 1.06 0.195 0.438
1.41 1.05 0.449 0.062
1.33 1.02 0.315 0.203
1.52 1.01 0.008 0.974
1.49 1.01 0.057 0.823
1.29 1.00 0.011 0.967
(table continues)
n asthma (comparing the Th2-high asthma subset with both the Th2-low
ompared with nonsensitized rhesus monkeys.
ates greater hyperreactivity, such that negative correlations with EC150
y rate of 20%.










iscovermal changes or slight decreases in the hyperreactivity of the 4
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tive at the presensitization time point. However, whenwe com-
pared the 8 animals in the sensitizedgroupand the 10 animals
in the nonsensitized group that were not hyperreactive before
sensitization and which had comparable levels of airway hy-
perreactivity at the presensitization time point, we found that
the sensitized group showed a greater increase in airway
hyperreactivity at the postsensitization time point than the non-
sensitized group, indicating that the sensitization protocol in-
duced airway hyperreactivity in the sensitized group (see Sup-
plemental Figure S2 at http://ajp.amjpathol.org).
The Rhesus Asthma Model Exhibits a Th2
Inflammation Gene Expression Signature in the
Lung Airways
To compare the molecular pathways and mediators in the
rhesus asthma model with those of human asthma, we
analyzed lung airway biopsies from all 12 sensitized and all
10 nonsensitized animals at the postsensitization time point.






‡ P§ ‡ P§ ‡
0.225 0.37 0.283 0.292 0.075
0.022 0.966 0.405 0.128 0.027
0.389 0.11 0.615 0.007 0.112
0.302 0.224 0.468 0.062 0.195
0.003 0.99 0.643 0.005 0.096
0.313 0.206 0.509 0.037 0.061
0.1 0.693 0.176 0.5 0.015
0.457 0.057 0.046 0.843 0.088
0.062 0.806 0.659 0.004 0.007
0.098 0.699 0.156 0.561 0.106
0.165 0.512 0.148 0.572 0.228
0.065 0.799 0.681 0.003 0.026
0.104 0.681 0.256 0.31 0.24
0.369 0.131 0.145 0.579 0.059
0.154 0.542 0.347 0.187 0.148
0.085 0.736 0.115 0.662 0.146
0.095 0.709 0.327 0.222 0.051
0.229 0.569 0.575 0.132 0.015
0.019 0.941 0.141 0.622 0.187
0.018 0.944 0.251 0.339 0.226
0.056 0.825 0.173 0.497 0.053
0.313 0.206 0.092 0.688 0.154
0.304 0.22 0.251 0.273 0.373
0.145 0.567 0.251 0.349 0.071
0.149 0.556 0.175 0.514 0.148Agilent Whole Human Genome expression microarraychips, and genes were assessed for differential expression
by considering pairwise comparisons between sensitized
and control animals. We assessed the genes that were
differentially expressed in the postsensitization time point
samples from sensitized rhesus monkeys (versus nonsen-
sitized) and compared them with the genes that were dif-
ferentially expressed in lung airway biopsies from a previ-
ously described cohort of mild-to-moderate asthmatic
patients who were not being treated with steroids (versus
healthy controls).5,6
Our previous studies identified a set of three genes
that are specifically induced in human asthmatic epithe-
lium, are directly regulated by the Th2 cytokine IL-13 in
vitro, and can serve as a surrogate marker of Th2 inflam-
mation in the lung.6,27 These three genes (periostin, chlo-
ride channel regulator 1/CLCA1, and serpin peptidase
inhibitor clade B member 2/serpinB2) are increased not
only in human asthmatic epithelial cell brushings but also
in matched lung biopsies and define a Th2-high subset of
patients who have airway eosinophilia, increased serum






P§ ‡ P§ ‡ P§
0.767 0.628 0.005 0.604 0.008
0.936 0.559 0.02 0.292 0.263
0.656 0.238 0.341 0.568 0.014
0.436 0.465 0.052 0.464 0.052
0.705 0.418 0.084 0.322 0.192
0.811 0.458 0.056 0.22 0.38
0.954 0.326 0.187 0.587 0.01
0.729 0.231 0.356 0.22 0.38
0.98 0.392 0.107 0.224 0.371
0.674 0.088 0.729 0.066 0.796
0.361 0.057 0.823 0.172 0.495
0.921 0.351 0.153 0.208 0.409
0.335 0.187 0.457 0.462 0.054
0.818 0.268 0.283 0.22 0.38
0.558 0.072 0.776 0.195 0.438
0.563 0.282 0.257 0.245 0.327
0.843 0.441 0.067 0.103 0.684
0.88 0.664 0.042 0.208 0.417
0.456 0.377 0.123 0.306 0.218
0.366 0.062 0.806 0.041 0.873
0.837 0.36 0.142 0.268 0.282
0.541 0.404 0.097 0.233 0.353
0.129 0.133 0.598 0.118 0.641
0.78 0.023 0.929 0.274 0.271
0.558 0.152 0.548 0.191 0.448Total
IgEAdditional analysis of lung biopsies from Th2-high asth-
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uniquely annotated genes that are highly intercorrelated
and that define a larger Th2 inflammation gene set in lung
biopsies, compared with the 3-gene set in lung epithe-
lium.5 Several other groups have also defined Th2 inflam-
mation gene sets, and many of the genes comprising our
epithelial 3-gene set and our biopsy 79-gene set have
also been identified by other groups in their Th2 inflam-
mation gene sets and/or have been previously shown
to be induced by the Th2 cytokines IL-4 and IL-
13.5,19,20,25,26,29–34
We found that periostin, CLCA1, and serpinB2 are
increased in rhesus asthma lung biopsies (Figure 3A).
Moreover, the human biopsy 79-gene set is correlated
between human asthma and rhesus asthma (Figure
3B). Taken together, these data indicate that there is a
strong Th2 inflammation gene signature in rhesus
asthma and that the expression of Th2 inflammation
genes is similar between human Th2-high asthma and
rhesus asthma.
Th2 Inflammation Genes Correlate with
Physiologic Measures of Th2 Inflammation and
Disease in the Rhesus Asthma Model
Because our Th2 inflammation genes correlated with phys-
iologic parameters of Th2 inflammation and disease in hu-
man asthma,5,6 we investigated whether this was also true
for the rhesus asthma model. We assessed the correlation
of our Th2 inflammation gene set at the postsensitization
time point in the rhesus asthma model with BALF eosino-
phils, BALF lymphocytes, peripheral blood eosinophils, total
serum IgE, HDM-specific serum IgE, and airway hyperre-
activity to methacholine. To reduce the statistical penalty for
multiple testing, we limited the genes tested to a subset of
25 genes from the previously defined 79-gene set in human
asthmatics. This 25-gene set was generated by first apply-
ing filters of a fold change  1.2 and a q-value  0.05 to
whole-genome expression profiles of lung airway biopsies
from the Th2-high subset of asthmatic patients (comparing
the Th2-high asthma subset with both the Th2-low asthma
subset and the healthy control subjects) to generate a 35-
gene set, followed by an additional filter of increased ex-
pression (fold change  1) in rhesus asthma lung airway
biopsies compared with nonsensitized control rhesus lung
airway biopsies to generate the final 25-gene set. Many
of the genes in the 25-gene set were modestly up-
regulated in rhesus lung airway biopsies with respect
to the mean fold change between sensitized and non-
sensitized groups, because of the heterogeneity of the
animals in each group. Importantly, however, there was
sufficient variability in gene expression and physio-
logic parameters in individual animals to support test-
ing for correlations.
With the use of a cutoff threshold corresponding to a
false discovery rate of 20%, we found that 10 of the 25
genes were correlated with BALF eosinophils, 6 of the 25
genes were correlated with HDM-specific serum IgE lev-
els and peripheral blood eosinophils, and 5 of the 25
genes were correlated with airway hyperreactivity. Thiscorrelation between Th2 inflammation genes and disease
parameters on an animal-to-animal basis in the sensitized
group is similar to that observed in human asthma.5,6
There was no correlation between the set of 25 genes
and total serum IgE and very little correlation between the
set of 25 genes and BALF lymphocytes, because only 1
of the 25 genes was correlated with BALF lymphocytes. A
summary of the correlation of the 25 genes with the var-
ious physiologic parameters is shown in Table 1, and a
plot of the correlation of each gene in the 25-gene set
with BALF eosinophils is shown in Supplemental Figure
S3 at http://ajp.amjpathol.org.
Comparison of Human, Rhesus, and Mouse
Asthma Gene Expression Profiles Shows
Common and Distinct Pathophysiologies
The most commonly used species in preclinical animal
models of asthma is the mouse. To assess which as-
pects of human Th2 asthma are recapitulated in rhesus
and mouse asthma models, we compared a published
lung gene expression profile in a standard mouse
asthma model with the airway biopsy gene expression
profiles in rhesus asthma and human Th2 asthma. We
reanalyzed the lung gene expression microarray data
from a published study of an acute ovalbumin-induced
asthma model in BALB/c mice (BALB/c OVA)21 with the
use of the same analytic methods that we applied to
our rhesus and human data sets, and compared the
Figure 4. Human asthma Th2 inflammation genes are also up-regulated in
rhesus and mouse models of asthma. Thirty-five genes that represent a Th2
inflammation signature in the Th2-high subset of human asthma, defined by
applying filters of a fold change 1.2 and a q-value of 0.05 to whole-genome
expression profiles of lung airway biopsies from the Th2-high subset of asth-
matic patients (comparing the Th2-high asthma subset with both the Th2-low
asthma subset and the healthy control subjects), were tested for differential
expression in the rhesus asthma model and an OVA-induced mouse asthma
model. The fold change of each gene in each model species that meets a false
discovery rate cutoff of 20% is plotted against the fold change of that gene in
human Th2-high asthma. The fold change of rhesus and mouse asthma model
genes that do not meet the false discovery rate cutoff is plotted as 1.0.
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and mouse genes defined by Homologene.35 Although
there are multiple variations of mouse asthma models
consisting of different sensitization and challenge pro-
tocols, as well as different antigens, the BALB/c OVA
mouse asthma model whose gene expression we an-
alyzed is the most commonly used version of mouse
asthma in the literature. As expected, our analysis of
the BALB/c OVA gene expression data set produced
results similar to those originally published.
When comparing genes that are commonly up-regu-
lated in human, rhesus, and BALB/c OVA mouse asthma,
we found that a dominant gene signature that is shared
among all three species contains genes that are associ-
ated with Th2 inflammation. Of the 35-gene set that rep-
resents the Th2 inflammation signature in the Th2-high
subset of human asthma, as described above, many of
the genes are also up-regulated in either sensitized rhe-
sus or sensitized mice, although few of the genes are
up-regulated in both species (Figure 4).
To more broadly assess the similarities and differences
between human, rhesus, and BALB/c OVA mouse
asthma, all genes differentially expressed in human Th2-
high asthma biopsies (comparing the Th2-high asthma
subset with both the Th2-low asthma subset and the
healthy control subjects) were examined for significant
differential expression in rhesus and BALB/c OVA
asthma. Most genes that were differentially expressed in
disease were specific to a single species, with 309 genes
in common between human and rhesus asthma and 217
genes in common between human and BALB/c OVA
asthma (Figure 5). Only 11 genes were up-regulated in all
three species (see Supplemental Table S3 at http://
Figure 5. A subset of genes is commonly up-regulated among human Th2-
high asthma, rhesus asthma, and/or mouse asthma. The Venn diagram de-
picts the total number of genes that are up-regulated in human Th2-high
asthma, HDM-sensitized rhesus monkeys, and OVA-sensitized BALB/c mice.
Intersections of the Venn diagram depict the total number of genes that are
shared by two or three species.ajp.amjpathol.org). Of these 11 genes, periostin has beenpreviously described to be associated with Th2 inflam-
mation and is produced downstream of IL-4 and IL-13
signaling.6,27
To determine which biological pathways in human Th2-
high asthma are specifically represented in either rhesus
or BALB/c OVA asthma, we used the Database for An-
notation, Visualization, and Integrated Discovery36 to
identify sets of genes from the Gene Ontology, SwissProt/
Protein Information Resource, KEGG, INTERPRO, and
SMART databases that are enriched among the genes
shared by human and rhesus asthma or human and
mouse asthma (last accessed May 13, 2010). A total of
30 groups with an adjusted P value of101 are specific
to human Th2-high asthma and rhesus asthma and de-
scribe biological processes (Table 2). These groups are
enriched for genes associated with extracellular matrix
biology, cell morphogenesis, nervous system biology,
immune host defense biology, and angiogenesis (Table
3). In contrast, only four groups with an adjusted P value
of 101 are specific to human Th2-high asthma and
BALB/c OVA asthma and describe biological processes
(Table 4). These groups include extracellular matrix biol-
ogy, sequence-specific DNA-binding proteins, and pro-
teins associated with developmental biology.
Table 2. Increased Expression of Biological Gene Sets in Both
Human Th2-High Asthma and the Rhesus Asthma
Model, as Identified by DAVID Analysis
DAVID term (biology) P*
Extracellular region part 4.19  105
Extracellular matrix 8.08  105
Proteinaceous extracellular matrix 1.90  104
Cellular component morphogenesis 3.77  104




Cell projection organization 0.00126
Axonogenesis 0.00156
Cell projection morphogenesis 0.00253
Neuron projection morphogenesis 0.00267
Cell morphogenesis involved in neuron
differentiation
0.00294
Neuron projection development 0.00313









Response to extracellular stimulus 0.0453
Neuron differentiation 0.0460







*Corrected by the method of Benjamini-Hochberg for multiple com-
parisons.DAVID, Database for Annotation, Visualization, and Integrated Dis-
covery.
covery.
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It is increasingly recognized that asthma is a heteroge-
neous disease1,2 and that a diversity of pathogenic
mechanisms can give rise to the common clinical mani-
Table 3. Genes that Comprise the Extracellular Matrix, Axonoge




ID Entrez gene ID




















































DAVID, Database for Annotation, Visualization, and Integrated Disfestations of variable airflow obstruction, airway hyperre-activity, and chronic airway inflammation that are ob-
served in human asthmatics. The composition of the
airway inflammation in the asthmatic lung has been stud-
ied by several groups and has been found to be hetero-
efense Response, and Angiogenesis Gene Sets Identified by
Asthma Model
ene symbol Gene name
OL18A1 Collagen, type XVIII, alpha 1
OL11A2 Collagen, type XI, alpha 2
N1 Fibronectin 1
RTAP Cartilage associated protein
ATN2 Matrilin 2
D44 CD44 molecule (Indian blood group)
OL15A1 Collagen, type XV, alpha 1
PARC Secreted protein, acidic, cysteine-rich
(osteonectin)
DAMTSL5 ADAMTS-like 5
OXL1 Lysyl oxidase-like 1
APLN1 Hyaluronan and proteoglycan link protein 1
NGPTL4 Angiopoietin-like 4
ST Dystonin
GP Matrix Gla protein
DAMTSL2 Similar to ADAMTS-like 2; ADAMTS-like 2
OL6A1 Collagen, type VI, alpha 1
MP7 Bone morphogenetic protein 7
OL6A1 Collagen, type VI, alpha 1
NT10A Wingless-type MMTV integration site family,
member 10A
IT Vitrin
PON2 Spondin 2, extracellular matrix protein
EMA6A Sema domain, transmembrane domain
(TM), and cytoplasmic domain,
(semaphorin) 6A
PL24 Ribosomal protein L24; ribosomal protein
L24 pseudogene 6
LITRK6 SLIT and NTRK-like family, member 6
FNB1 Ephrin-B1
ST Dystonin
RKCA Protein kinase C, alpha
KX2-1 NK2 homeobox 1
HX4 LIM homeobox 4
NAP25 Synaptosomal-associated protein, 25kDa
MP7 Bone morphogenetic protein 7
TN4R Reticulon 4 receptor
NC5C Unc-5 homolog C (C. elegans)
PON2 Spondin 2, extracellular matrix protein
ALP7 NLR family, pyrin domain containing 7
OS2A Nitric oxide synthase 2, inducible
CL13 Chemokine (C-C motif) ligand 13
CL26 Chemokine (C-C motif) ligand 26
N1 Fibronectin 1
D44 CD44 molecule (Indian blood group)
YSLTR1 Cysteinyl leukotriene receptor 1
CL26 Chemokine (C-C motif) ligand 26
2RX7 Purinergic receptor P2X, ligand-gated ion
channel, 7
MP2 Bone morphogenetic protein 2
NLY Granulysin
CSIT ECSIT homolog (Drosophila)
NGPTL4 Angiopoietin-like 4
AV3 Vav 3 guanine nucleotide exchange factor
POLD1 Apolipoprotein L domain containing 1
N1 Fibronectin 1
GFL7 EGF-like-domain, multiple 7






















































Cgeneous in disease,1–4 with one common subtype of
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AJP October 2011, Vol. 179, No. 4asthma defined by eosinophilic lung inflammation that is
associated with Th2 inflammatory gene expression.5,6 A
better understanding of the pathophysiology of eosino-
philic/Th2-high asthma and other asthma subtypes will
facilitate the identification of novel asthma therapeutics,
as well as the identification of the appropriate patient
populations for treatment with these therapies.
Studies of nonhuman primate models of asthma have
yielded important insights into human asthma pathogen-
esis, given the strong similarities between nonhuman pri-
mates and humans. Although mice are the most com-
monly used species in preclinical asthma research,
studies of nonhuman primate models of asthma can com-
plement and supplement studies of mouse models of
asthma, given the limitations of mouse asthma models in
modeling human disease.14,37–40 Here, we have as-
sessed the genomewide lung gene expression profile of
an allergic asthma model induced in rhesus monkeys by
HDM and have compared it with the lung gene expres-
sion profiles of the eosinophilic/Th2-high subtype of hu-
man asthma and a commonly used mouse asthma
model. We find that a dominant gene expression signa-
ture in all three species is a Th2 inflammation gene sig-
nature. Significantly, there is a strong correlation between
a prespecified set of human Th2 inflammation genes in
human Th2-high asthma and in the rhesus asthma model.
In addition, similar to studies of this lung Th2 inflammation
gene set in human asthma,5,6 we find that the Th2 inflam-
mation gene set correlates with physiologic measures of
Th2 inflammation and disease in rhesus asthma, includ-
ing BALF eosinophils, peripheral blood eosinophils,
HDM-specific serum IgE, and airway hyperreactivity.
Thus, consistent with previous reports,11 the rhesus
asthma model exhibits many features of human Th2-high
asthma. In support of our observations, others have also
reported gene expression that is associated with Th2
inflammation in the lungs or BALF of nonhuman primate
models of asthma, including a previous study of the
HDM-induced rhesus asthma model studied here.10,25,26
Differences in the specific genes detected in our study
versus previous studies of nonhuman primate asthma
models may be due to i) differences in assessed genes
(our study used a prespecified gene set that was gener-
ated by applying statistical cutoffs to a human asthma
biopsy microarray gene expression data set, whereas
Table 4. Increased Expression of Biological Gene Sets in Both
Human Th2-High Asthma and the BALB/c OVA
Mouse Asthma Model, as Identified by DAVID
Analysis
DAVID term (biology) P*
Extracellular structure organization 0.00210
Sequence-specific DNA binding 0.0160
Developmental protein 0.0540
Embryonic organ development 0.0720
*Corrected by the method of Benjamini-Hochberg for multiple com-
parisons.
DAVID, Database for Annotation, Visualization, and Integrated Dis-
covery.previously published studies assessed hand-curatedgene lists), ii) differences in assay sensitivity (we as-
sessed gene expression levels by microarray, whereas
some previously published studies assessed gene ex-
pression levels by quantitative PCR), and/or iii) differ-
ences in animal model samples (we assessed airway
biopsy gene expression, whereas previously published
studies assessed either whole lung or BALF cell gene
expression).
Additional analysis of the lung gene expression pro-
files of human, rhesus, and BALB/c OVA mouse asthma
showed that only a small subset of genes is shared
among the three different species. The lack of significant
gene overlap among the three species may be due to
several reasons, including i) imperfect cross-hybridiza-
tion between rhesus mRNA transcripts and human mi-
croarray probes, which would reduce the number of rhe-
sus genes that can be assessed by microarray; ii)
incomplete orthology between human and mouse genes,
which would reduce the number of mouse genes that can
be compared with human genes; and iii) limitations in the
ability of the animal models to fully mimic human disease
biology. Imperfect cross-hybridization between rhesus
mRNA transcripts and human microarray probes be-
cause of differences in homology between rhesus and
human gene sequences would lead to false-negative sig-
nals. We calculate that 99% of human genes lie in regions
possessing synteny to a sequenced portion of the rhesus
macaque genome, and that 96% of the human probes on
the Agilent microarray platform are perfect matches in
sequence to the rhesus genes. In addition, analysis of our
human and rhesus microarray expression data indicates
that the average expression intensity of each gene is
similar between the two species. Thus, imperfect cross-
hybridization between rhesus mRNA transcripts and hu-
man microarray probes is unlikely to be a main cause of
the lack of significant gene overlap between rhesus and
human gene expression. Ultimately, the main effect of
microarray platform and species orthology limitations on
our conclusions is probably a potential underestimation
of the similarities between human asthma and the rhesus
and mouse asthma models.
When we compared the genes that are shared by
human Th2-high asthma and rhesus asthma with the
genes that are shared by human Th2-high asthma and
BALB/c OVA mouse asthma, we found that some of the
biological pathways that are present in the gene expres-
sion profile of human Th2-high asthma are better repre-
sented in the gene expression profile of the rhesus
asthma model than that of the BALB/c OVA model. These
include extracellular matrix biology, cell morphogenesis,
nervous system biology, immune host defense biology,
and angiogenesis. One limitation of our approach, which
may have influenced the outcomes of our analyses, is
that we assessed airway biopsy gene expression from
human and rhesus and total lung homogenate gene ex-
pression from mouse. Thus, the composition of the tis-
sues being compared among human, rhesus, and mouse
are different. However, a previously published study of
gene expression in total lung homogenate from an aller-
gic asthma model induced in cynomolgus monkeys by
Ascaris suum antigen also identified Th2 inflammation
1678 Abbas et al
AJP October 2011, Vol. 179, No. 4and remodeling genes, although not nervous system or
angiogenesis biology.26 Moreover, it should be noted
that the pattern of immune cell accumulation in the lung
after allergen challenge differs between rodents and pri-
mates. Whereas in mice the immune cell accumulation is
primarily perivascular with diffuse peribronchial accumu-
lation, in humans and rhesus the immune cell accumula-
tion is primarily in the larger conducting airways. As such,
the biological pathways present in the areas of the mouse
airways that are comparable to the areas sampled by
biopsies in humans and rhesus monkeys are probably
more divergent than those present in total mouse lung
homogenate.
Subepithelial fibrosis of the lung, which consists of
extracellular matrix deposition in the basement mem-
brane, is a pathological characteristic of asthma and
may contribute to irreversible lung obstruction.41,42 A
previous study of the rhesus asthma model showed
increased thickening of the basement membrane, as
assessed by histology.11 In contrast, commonly used
short-term mouse models of asthma, such as the
BALB/c OVA model that we analyzed in this study,21 do
not develop subepithelial fibrosis and lung remodeling,
although more chronic mouse models of asthma can
develop some features of fibrosis and remodeling.39
Neuronal dysfunction and dysregulation, encompass-
ing activation of both the parasympathetic and sympa-
thetic nervous systems, may contribute to the patho-
genesis of asthma.43–45 Neural mediators can have
direct effects on smooth muscle, airway glands, and
alveolar walls; there is also substantial interaction be-
tween the nervous system and the immune system in
the lungs of asthmatic persons. The lung vasculature is
increased in asthmatics, and the degree of vascular
abnormalities in asthma is associated with asthma se-
verity.46–48 Vascularization is not increased in nontrans-
genic allergen-induced mouse asthma models,49,50 al-
though overexpression of vascular endothelial growth factor
in the mouse lung results in increased vascularization, Th2
inflammation, and remodeling.49,51 In contrast, in the rhesus
monkey model of asthma, bronchial vascular density was
increased at the mid-to-lower airway generations and was
independent of changes in the interstitial compartment.7
Given the multiple variations of mouse asthma mod-
els in the literature, comprising differences in sensiti-
zation and challenge protocols, differences in aller-
gens, and differences in mouse strains, it was not
possible for us to compare human Th2-high asthma
gene expression with that of every mouse asthma
model. We therefore chose to compare lung gene ex-
pression in human asthma, rhesus asthma, and the
most commonly used version of mouse asthma in the
literature, which is an acute OVA-induced mouse
asthma model in the BALB/c strain. Some of the gene
expression features of human Th2-high asthma that are
observed in the rhesus asthma model, but not in the
mouse asthma model, may be present in other versions
of mouse asthma that incorporate a more chronic sen-
sitization and challenge protocol or that use HDM
antigen. To address this, we performed additional
comparisons of the gene expression profile of humanTh2-high asthma with those of a chronic OVA-induced
mouse asthma model16 and an acute HDM-induced
mouse asthma model,18 both of which are publically
available. The chronic OVA-induced mouse asthma
models share features of cell cycle/cell division, cellu-
lar substructures, lymphocyte/T-cell activation and dif-
ferentiation, immune response/inflammation, extracel-
lular region, chemotaxis, and chitinase activity with
human Th2-high asthma (see Supplemental Table S4
at http://ajp.amjpathol.org). The acute HDM-induced
mouse asthma model shares features of cell cycle/cell
division, chemotaxis, extracellular region/extracellular
matrix, immune response/inflammation, and chitinase
activity with human Th2-high asthma (see Supplemen-
tal Table S5 at http://ajp.amjpathol.org). However, sim-
ilar to the acute OVA-induced mouse asthma model,
neither the chronic OVA-induced mouse asthma model
nor the acute HDM-induced mouse asthma model ex-
hibits features of neural biology or angiogenesis, fea-
tures that are shared between the rhesus asthma
model and human Th2-high asthma.
Our study is the first to our knowledge to directly
compare genomewide human asthma lung gene ex-
pression with that of any preclinical asthma model,
regardless of species. We find that a lung Th2 inflam-
mation gene signature that is present in the eosinophil-
ic/Th2-high subtype of human asthma is modeled by a
HDM antigen-induced allergic asthma model in rhesus
monkeys, as well as by a BALB/c OVA mouse asthma
model. In addition, some gene profiles that are present
in human Th2-high asthma are better represented in
the gene expression profile of the rhesus asthma
model, compared with that of the BALB/c OVA mouse
asthma model. These include some inflammatory path-
ways, subepithelial fibrosis and remodeling, angiogen-
esis, and neural biology that may be associated with
neurogenic inflammation. Further study of the rhesus
asthma model may complement and supplement stud-
ies of mouse asthma models, yield novel insights into
the pathogenesis of human Th2-high asthma, and aid
in the identification of new therapeutic targets and
disease biomarkers for asthma, including potentially
some of the genes reported in this study.
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